Eli Lilly plans to acquire the American biotech company Kelonia for up to $7 billion in cash

Mars Finance News, April 20—According to reports, Eli Lilly plans to acquire US biotech company Kelonia Therapeutics with cash of up to $7 billion. Kelonia Therapeutics was founded in 2020, is headquartered in Cambridge, Massachusetts, USA, and is a privately held clinical-stage biotechnology company. (Broad Perspective)

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin